PD-L1 antibody pharmaceutical composition and use thereof
US11654194B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 15, 2018 |
| Grant date | May 23, 2023 |
| Priority date | — |
| Expiry date | May 31, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a PD-L1 antibody pharmaceutical composition and use thereof. In particular, the present invention provides a pharmaceutical composition comprising the PD-L1 antibody or an antigen-binding fragment thereof in a succinate buffer. In addition, the pharmaceutical composition may also contain a sugar and a nonionic surfactant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.